Medtronic's Trading Volume Plummets 61.43% Ranking 182nd Amid FDA Recall

On March 24, 2025, Medtronic's trading volume was $489 million, down 61.43% from the previous day, ranking 182nd in the day's stock market. Medtronic (MDT) fell 0.22%, marking its fifth consecutive day of decline, with a 3.45% drop over the past five days.

Medtronic's stock price experienced a decline following a notice from the U.S. Food and Drug Administration (FDA) regarding a product recall. The FDA classified the recall of Medtronic's embolization devices as the most serious type, which led to a significant drop in the company's shares. This recall was initiated after reported deaths, further impacting investor confidence.

Despite the setback, Medtronic has seen some positive developments. The company was named one of the 2025 World's Most Ethical Companies for the third time by Ethisphere, recognizing its commitment to business integrity through robust ethics, compliance, and governance programs. Additionally, Medtronic declared a $0.70 dividend, demonstrating its financial stability and commitment to shareholder returns.

Medtronic's recent clinical trials have also shown promising results. The SMART trial, which compared the Evolut TAVR system to the SAPIEN system in patients with small aortic annuli, showed positive performance for the Evolut system. This data supports the superior valve performance of the Evolut TAVR system in small annulus patients, which could be a significant advantage for the company in the competitive medical device market.